ETFs
B
BIIB
Biogen Inc
177.35
+1.33+0.76%After Hours: 177.22 -0.13 -0.07%17:05 04/17 EDT
OPEN/PREV CLOSE176.29/176.02
TODAY RANGE175.69-178.41
VOL1.24M
MARKET CAP26.03B
52 WEEK RANGE114.66-202.41
AVG VOL (3M)1.25M
% TURNOVER0.84%
TURNOVER--
P/E (TTM)20.18
% RANGE1.54%
EPS(TTM)8.79
P/E(FORWARD)15.04
P/B1.425
BVPS124.45
DIVIDEND--
P/S2.631
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP25.95B
SHARES OUTSTANDING146.76M
NEXT EARNINGS04/29-05/04
FREE FLOAT146.32M
LOT SIZE1
EX-DATE02/02/2017
News
Press Releases
Financial Reports
Profile
Seeking Alpha·1d ago
Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks
MarketWatch·1d ago
These Alzheimer’s drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Simply Wall St·1d ago
Biogen’s Apellis Deal Reshapes Growth Story And Pipeline Priorities
Benzinga·2d ago
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
The Motley Fool·3d ago
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?
Simply Wall St·3d ago
How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors
Seeking Alpha·5d ago
Biogen raised to Overweight at Piper Sandler on Apellis buyout
Same Industry
Name/Symbol
Change%
Price